Proteome Sciences plc (LON:PRM)‘s stock had its “corporate” rating reiterated by research analysts at FinnCap in a research note issued to investors on Thursday. They currently have a GBX 12 ($0.15) price target on the stock. FinnCap’s price target indicates a potential upside of 144.90% from the stock’s current price.
Proteome Sciences plc (LON:PRM) opened at 4.888 on Thursday. The firm’s market capitalization is GBX 11.14 million. The stock’s 50 day moving average is GBX 5.30 and its 200 day moving average is GBX 9.99. Proteome Sciences plc has a 1-year low of GBX 4.57 and a 1-year high of GBX 23.94.
In related news, insider Martin Diggle bought 105,590 shares of the business’s stock in a transaction that occurred on Wednesday, January 4th. The shares were acquired at an average cost of GBX 6 ($0.07) per share, with a total value of £6,335.40 ($7,891.63).
About Proteome Sciences plc
Proteome Sciences plc is a protein biomarker company specializing in proteomics and peptidomics services and applications, and mass spectrometry (MS) protein analysis. The Company is engaged in biomarker research and development in applied proteomics and workflows using its techniques to detect and characterize differentially expressed proteins in diseases for diagnostic, prognostic and therapeutic applications.